Disease · EFO_0009909
stage 5 chronic kidney disease
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. stage 5 chronic kidney disease. Diseases, record EFO_0009909. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0009909
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- stage 5 chronic kidney disease
- Open Targets ID
- EFO_0009909
- Other names
- End stage renal disease, End stage renal failure, chronic renal failure
- Highest stage of its drugs
- Approval, for 2 of its 136 drugs, from PMDA
Source Open Targets
Drugs136
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| LANTHANUM CARBONATE | CHEMBL2096647 | Small molecule | Approval | PMDA | 5 | 4 | 4 | Drugs and targets |
| BIXALOMER | CHEMBL4297202 | Small molecule | Approval | PMDA | 1 | 0 | 0 | Drugs and targets |
| EPOETIN ALFA | CHEMBL1201565 | Protein | Phase 3 | ClinicalTrials.gov | 7 | 7 | 6 | Drugs and targets |
| ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) | CHEMBL2108981 | Phase 3 | ClinicalTrials.gov | 4 | 4 | 1 | Drugs and targets | |
| DARBEPOETIN ALFA | CHEMBL1201566 | Protein | Phase 3 | ClinicalTrials.gov | 4 | 4 | 3 | Drugs and targets |
| HUMAN IMMUNOGLOBULIN G | CHEMBL1201599 | Phase 3 | ClinicalTrials.gov | 4 | 4 | 0 | Drugs and targets | |
| TICAGRELOR | CHEMBL398435 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| CALCIUM ACETATE | CHEMBL1200800 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| EPOETIN BETA | CHEMBL2109092 | Protein | Phase 3 | ClinicalTrials.gov | 3 | 3 | 1 | Drugs and targets |
| FERRIC CITRATE | CHEMBL3301597 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
1 to 10 of 136
See all 136 drugsTargets157
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| VDR | Vitamin D3 receptor | 5 | Vitamin D receptor agonist | Phase 2/3 | https://conductscience.org/library/genes/7421 | Drugs and targets |
| ACE | Angiotensin-converting enzyme | 4 | Angiotensin-converting enzyme inhibitor | Phase 3 | https://conductscience.org/library/genes/1636 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 4 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| DPP4 | Dipeptidyl peptidase 4 | 3 | Dipeptidyl peptidase IV inhibitor | Phase 3 | https://conductscience.org/library/genes/1803 | Drugs and targets |
| EPOR | Erythropoietin receptor | 3 | Erythropoietin receptor agonist | Phase 3 | https://conductscience.org/library/genes/2057 | Drugs and targets |
| FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | 3 | FK506-binding protein 1A inhibitor | Phase 1 | https://conductscience.org/library/genes/2280 | Drugs and targets |
| HMGCR | 3-hydroxy-3-methylglutaryl-coenzyme A reductase | 3 | HMG-CoA reductase inhibitor | Phase 2 | https://conductscience.org/library/genes/3156 | Drugs and targets |
| AR | Androgen receptor | 2 | Androgen Receptor agonist; Androgen Receptor degrader | Phase 2 | https://conductscience.org/library/genes/367 | Drugs and targets |
| CASR | Extracellular calcium-sensing receptor | 2 | Calcium sensing receptor agonist; Calcium sensing receptor positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/846 | Drugs and targets |
| EGLN1 | Egl nine homolog 1 | 2 | Egl nine homolog 1 inhibitor; Hypoxia-inducible factor prolyl hydroxylase inhibitor | Phase 3 | https://conductscience.org/library/genes/54583 | Drugs and targets |
1 to 10 of 157
See all 157 targetsTrials123
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 9 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03817463 | A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes | 327,624 | 2024-09-23 | Diabetes Mellitus, Type 2 | DEXTROSE, EMPAGLIFLOZIN | Its record names the disease | ClinicalTrials.gov | |
| NCT02052310 | Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants | Phase 3 | 1,043 | 2021-10-01 | Anemia in Incident Dialysis Patients | EPOETIN ALFA, ROXADUSTAT | Its record names the disease | ClinicalTrials.gov |
| NCT02278341 | Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis | Phase 3 | 838 | 2020-08-26 | Anemia, End Stage Renal Disease (ESRD) | DARBEPOETIN ALFA, EPOETIN ALFA, ROXADUSTAT | Its record names the disease | ClinicalTrials.gov |
| NCT00987389 | Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis | Phase 3 | 704 | 2020-05-26 | Granulomatosis With Polyangiitis (Wegener's) (GPA), Microscopic Polyangiitis (MPA) | PREDNISOLONE | Its record names the disease | ClinicalTrials.gov |
| NCT01191255 | A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on Dialysis | Phase 3 | 441 | 2014-12-10 | Hyperphosphatemia, Kidney Failure | CALCIUM ACETATE, FERRIC CITRATE, SEVELAMER CARBONATE | Its record names the disease | ClinicalTrials.gov |
| NCT00237718 | Provision of Antioxidant Therapy in Hemodialysis (PATH) Study | Phase 2 | 385 | 2011-10-05 | End-stage Renal Disease | LIPOIC ACID, ALPHA, VITAMIN E | Its record names the disease | ClinicalTrials.gov |
| NCT03643965 | Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy | Phase 3 | 365 | 2024-12-03 | Primary IgA Nephropathy | BUDESONIDE | Its record names the disease | ClinicalTrials.gov |
| NCT03824587 | Study to Evaluate the Efficacy of Tenapanor as Adjunctive Therapy to Phosphate Binder Therapy | Phase 2/3 | 236 | 2023-03-06 | Hyperphosphatemia | TENAPANOR | Its record names the disease | ClinicalTrials.gov |
| NCT01698775 | A Study of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019) | Phase 3 | 213 | 2017-02-23 | Type 2 Diabetes Mellitus | GLIPIZIDE, INSULIN HUMAN, OMARIGLIPTIN | Its record names the disease | ClinicalTrials.gov |
| NCT01554982 | A Long-Term Safety Extension Trial of Ferric Citrate in Patients With End-Stage Renal Disease (ESRD) on Dialysis | Phase 3 | 168 | 2016-07-13 | End Stage Renal Disease, Kidney Failure, Renal Failure, Hyperphosphatemia, ESRD | FERRIC CITRATE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 123
See all 123 trialsComparisons in its trials33
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| SGLT-2i (Incl. Empa) (Matched to DPP-4i) vs DPP-4i (Matched to SGLT-2i): deaths from any cause | 1,371 of 163,812 | 2,524 of 163,812 | 327,624 | NCT03817463 | Trial comparisons |
| Roxadustat vs Epoetin Alfa: deaths from any cause | 64 of 522 | 54 of 517 | 1,039 | NCT02052310 | Trial comparisons |
| Roxadustat vs Epoetin Alfa: serious adverse events | 234 of 522 | 218 of 517 | 1,039 | NCT02052310 | Trial comparisons |
| Roxadustat vs ESA (Erythropoiesis-Stimulating Agent): deaths from any cause | 78 of 414 | 59 of 420 | 834 | NCT02278341 | Trial comparisons |
| Roxadustat vs ESA (Erythropoiesis-Stimulating Agent): serious adverse events | 210 of 414 | 189 of 420 | 834 | NCT02278341 | Trial comparisons |
| Plasma Exchange vs No Plasma Exchange: Number of Participants With Sustained Remission | 200 of 352 | 197 of 352 | 704 | NCT00987389 | Trial comparisons |
| Plasma Exchange vs No Plasma Exchange: Composite of i) All-cause Mortality or ii) End-stage Renal Disease | 100 of 352 | 109 of 352 | 704 | NCT00987389 | Trial comparisons |
| Plasma Exchange vs No Plasma Exchange: deaths from any cause | 46 of 352 | 53 of 352 | 704 | NCT00987389 | Trial comparisons |
| Plasma Exchange vs No Plasma Exchange: serious adverse events | 225 of 352 | 224 of 352 | 704 | NCT00987389 | Trial comparisons |
| Nefecon vs Placebo Oral Capsule: Part B: Proportion of Patients Without Microhematuria | 94 of 182 | 59 of 182 | 364 | NCT03643965 | Trial comparisons |
1 to 10 of 33
See all 33 comparisons in its trialsPapers from its trials93
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_0009909
GET https://conductscience.org/api/diseases/v1/EFO_0009909/drugs?page=2